


Figure 1




= SOLID SUPPORT


R = TERMINAL PROTECTING GROUP
 FOR EXAMPLE:
 DIMETHOXYTRITYL (DMT)

(1) = CLEAVABLE LINKER
 (FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
 INVERTED DEOXYABASIC SUCCINATE)

(2) = CLEAVABLE LINKER
 (FOR EXAMPLE: NUCLEOTIDE SUCCINATE OR
 INVERTED DEOXYABASIC SUCCINATE)



INVERTED DEOXYABASIC SUCCINATE
 LINKAGE



GLYCERYL SUCCINATE LINKAGE

Figure 2




Figure 3






Figure 4



POSITIONS (NN) CAN COMPRISE ANY NUCLEOTIDE, SUCH AS DEOXYNUCLEOTIDES
(eg. THYMIDINE) OR UNIVERSAL BASES
B = ABASIC, INVERTED ABASIC, INVERTED NUCLEOTIDE OR OTHER TERMINAL CAP
THAT IS OPTIONALLY PRESENT
L = GLYCERYL MOIETY THAT IS OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR PHOSPHORODITHIOATE

Figure 5



lower case = 2'-O-Methyl or 2'-deoxy-2'-fluoro
italic lower case = 2'-deoxy-2'-fluoro
underline = 2'-O-methyl

ITALIC UPPER CASE = DEOXY
B = INVERTED DEOXYABASIC
L = GLYCERYL MOIETY OPTIONALLY PRESENT
S = PHOSPHOROTHIOATE OR
PHOSPHORODITHIOATE

Figure 9: Target site Selection using siRNA





Figure 10



R = O, S, N, alkyl, substituted alkyl, O-alkyl, S-alkyl, alkaryl, or aralkyl
 B = Independently any nucleotide base, either naturally occurring or chemically modified, or optionally H (abasic).

Figure 11: Modification Strategy

